株探米国株
日本語 英語
エドガーで原本を確認する
0000001800FALSENew York Stock ExchangeCHX00000018002026-04-162026-04-160000001800exch:XNYS2026-04-162026-04-160000001800exch:XCHI2026-04-162026-04-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 16, 2026
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________

Illinois 1-2189 36-0698440
(State or other Jurisdiction
of Incorporation)		 (Commission File Number) (IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par Value ABT
New York Stock Exchange
NYSE Texas
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.


Item 2.02    Results of Operations and Financial Condition
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No. Exhibit
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: April 16, 2026 By: /s/ Philip P. Boudreau
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 abt-2026q1xexhibitx991.htm EX-99.1 Document

Exhibit 99.1
image.jpg
  News Release

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

–First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent
–Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market
–Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1
–Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences

ABBOTT PARK, Ill., April 16, 2026 — Abbott today announced financial results for the first quarter ended March 31, 2026.

•First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.
•First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.
•On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.
•Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
•Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
•In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.
•In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
•In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre® achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.

"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."
 
Page 1 of 15

FIRST-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)
 Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices
U.S. 4,274  844  905  —  2,523 
International 6,890  1,173  1,275  1,426  3,016 
Total reported 11,164  2,017  2,180  1,426  5,539 
% Change vs. 1Q25
U.S. 2.5  (11.6) 3.8  n/a 7.9 
International 11.3  (1.5) 7.8  13.2  18.0 
Total reported 7.8  (6.0) 6.1  13.2  13.2 
Total reported excl. foreign exchange impact 3.8  (7.7) 2.5  9.0  8.1 
Comparable sales growth 3.7  (7.7) 1.8  9.0  8.5 
    U.S. 2.5  (11.6) 2.0  n/a 8.7 
    International 4.6  (4.7) 1.6  9.0  8.3 

Refer to page 13 for a reconciliation of comparable sales growth.



Page 2 of 15


Nutrition

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)
 Total Pediatric Adult
U.S. 844  511  333 
International 1,173  442  731 
Total reported 2,017  953  1,064 
% Change vs. 1Q25
U.S. (11.6) (13.0) (9.2)
International (1.5) (2.6) (0.9)
Total reported (6.0) (8.5) (3.6)
Total reported excl. foreign exchange impact (7.7) (9.7) (5.9)
Comparable sales growth (7.7) (9.7) (5.9)
    U.S. (11.6) (13.0) (9.2)
    International (4.7) (5.3) (4.3)
Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of several new products, are expected to contribute to improved volume growth over the course of the year.







Page 3 of 15


Diagnostics*

First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)
 Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics
U.S. 905  347  93  465 
International 1,275  925  3  347 
Total reported 2,180  1,272  96  812 
% Change vs. 1Q25
U.S. 3.8  4.5  n/a (13.8)
International 7.8  9.5  n/a 2.8 
Total reported 6.1  8.1  n/a (7.4)
Total reported excl. foreign exchange impact 2.5  3.3  n/a (9.6)
Comparable sales growth 1.8  3.3  13.4  (9.6)
    U.S. 2.0  4.5  13.2  (13.8)
    International 1.6  2.8  19.2  (2.7)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to page 13 for a reconciliation of comparable sales growth.

Worldwide Diagnostics sales increased 6.1 percent on a reported basis and increased 1.8 percent on a comparable basis.

Worldwide Core Laboratory Diagnostics results were driven by growth in the U.S., Europe and Latin America. Sales of Core Laboratory diagnostic tests increased on both a year-over-year and sequential basis.

Rapid and Molecular Diagnostics results reflect lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.

Results in Cancer Diagnostics reflect Abbott's acquisition of Exact Sciences, which closed on March 23, 2026. Growth in Cancer Diagnostics was driven by double-digit growth of Cologuard® and sales of Cancerguard®, a multi-cancer screening test that launched last year.





Page 4 of 15


Established Pharmaceuticals

First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)
 Total Key Emerging Markets Other
U.S. —  —  — 
International 1,426  1,089  337 
Total reported 1,426  1,089  337 
% Change vs. 1Q25
U.S. n/a n/a n/a
International 13.2  12.9  14.1 
Total reported 13.2  12.9  14.1 
Total reported excl. foreign exchange impact 9.0  9.4  7.9 
Comparable sales growth 9.0  9.4  7.9 
    U.S. n/a n/a n/a
    International 9.0  9.4  7.9 

Established Pharmaceuticals sales increased 13.2 percent on a reported basis and 9.0 percent on a comparable basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 12.9 percent on a reported basis and 9.4 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.





Page 5 of 15


Medical Devices

First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)
 Total Rhythm Management Electro-
physiology*		 Heart Failure Vascular Structural Heart* Neuromodulation Diabetes Care
U.S. 2,523  339  378  292  291  224  177  822 
International 3,016  345  410  97  486  354  66  1,258 
Total reported 5,539  684  788  389  777  578  243  2,080 
% Change vs. 1Q25
U.S. 7.9  11.5  13.7  11.4  8.6  (9.5) 0.7  9.8 
International 18.0  22.9  19.6  25.2  10.0  25.2  27.2  16.6 
Total reported 13.2  17.0  16.7  14.6  9.5  9.0  6.8  13.8 
Total reported excl. foreign exchange impact 8.1  12.5  12.5  12.2  4.9  3.6  4.1  7.4 
Comparable sales growth 8.5  12.5  12.5  12.2  4.9  6.8  4.1  7.4 
    U.S. 8.7  11.5  13.7  11.4  8.6  (3.6) 0.7  9.8 
    International 8.3  13.5  11.2  14.9  2.7  15.0  15.5  5.7 

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

Refer to page 13 for a reconciliation of comparable sales growth.

Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 14.2 percent on a reported basis and 7.6 percent on a comparable basis.





Page 6 of 15


Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 409th Consecutive Quarterly Dividend
On Feb. 20, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

Page 7 of 15


— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika McLoughlin, 224-399-5082
Randy Blakley, 224-668-0036
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965

1.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.

Page 8 of 15


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Quarter Ended March 31, 2026 and 2025
(in millions, except per share data)
(unaudited)




1Q26 1Q25 % Change
Net Sales $11,164 $10,358 7.8 
Cost of products sold, excluding amortization expense 4,890  4,468  9.5 
Amortization of intangible assets 422  420  0.3 
Research and development 767  716  7.2 
Selling, general, and administrative 3,740  3,061  22.2 
Total Operating Cost and Expenses 9,819  8,665  13.3 
Operating Earnings 1,345  1,693  (20.6)
Interest expense, net 68  49  37.4 
Net foreign exchange (gain) loss (13) (7) n/m
Other (income) expense, net (159) (127) 24.8 
Earnings before taxes 1,449  1,778  (18.5)
Taxes on Earnings 372  453  (18.0) 1)
Net Earnings $1,077 $1,325 (18.7)
Net Earnings excluding Specified Items, as described below $2,022 $1,919 5.4  2)
Diluted Earnings per Common Share $0.61 $0.76 n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below $1.15 $1.09 5.5  2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,747  1,747 
NOTES:
See tables on page 11 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.

Page 9 of 15


1)2026 Taxes on Earnings includes the recognition of approximately $50 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $945 million, or $0.54 per share, for intangible amortization, charges related to restructuring, acquisitions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of $594 million, or $0.33 per share, for intangible amortization, charges related to investment impairments, restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Page 10 of 15


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Quarter Ended March 31, 2026 and 2025
(in millions, except per share data)
(unaudited)
1Q26
As Reported (GAAP) Specified Items As Adjusted
Intangible Amortization
 $ 422  $ (422) $ — 
Gross Margin
 5,852  432  6,284 
R&D
 767  (24) 743 
SG&A
 3,740  (473) 3,267 
Other (income) expense, net
 (159) (7) (166)
Earnings before taxes
 1,449  936  2,385 
Taxes on Earnings
 372  (9) 363 
Net Earnings
 1,077  945  2,022 
Diluted Earnings per Share
 $ 0.61  $ 0.54  $ 1.15 

Specified items reflect intangible amortization expense of $422 million and other net expenses of $514 million associated with restructuring actions, acquisitions, and other net expenses. See page 14 for additional details regarding specified items.
1Q25
As Reported (GAAP) Specified Items As Adjusted
Intangible Amortization
 $ 420  $ (420) $ — 
Gross Margin
 5,470  448  5,918 
R&D
 716  (27) 689 
SG&A
 3,061  (10) 3,051 
Other (income) expense, net
 (127) (35) (162)
Earnings before taxes
 1,778  520  2,298 
Taxes on Earnings
 453  (74) 379 
Net Earnings
 1,325  594  1,919 
Diluted Earnings per Share
 $ 0.76  $ 0.33  $ 1.09 

Specified items reflect intangible amortization expense of $420 million and other net expenses of $100 million associated with restructuring actions, acquisitions, investment impairments and other net expenses. See page 15 for additional details regarding specified items.

Page 11 of 15


A reconciliation of the first-quarter tax rates for 2026 and 2025 is shown below:
1Q26
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 1,449  $ 372  25.6 % 1)
Specified items 936  (9)
Excluding specified items $ 2,385  $ 363  15.2 %
1Q25
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 1,778  $ 453  25.5 % 2)
Specified items 520  (74)
Excluding specified items $ 2,298  $ 379  16.5 %
1)2026 Taxes on Earnings includes the recognition of approximately $50 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.






Page 12 of 15


Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
First Quarter Ended March 31, 2026 and 2025
($ in millions)
(unaudited)

1Q26 1Q25 % Change vs. 1Q25
Non-GAAP
Abbott Reported Impact of acquisition (a) Impact
of multi-year agreement (b)		 Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact
of multi-year agreement (b)		 Comparable Revenue Reported Comparable
Total Company 11,164  706  (8) (414) 11,448  10,358  707  (24) 11,041  7.8  3.7 
U.S. 4,274  681  (8) —  4,947  4,168  684  (24) 4,828  2.5  2.5 
Intl 6,890  25  —  (414) 6,501  6,190  23  —  6,213  11.3  4.6 
Total Diagnostics 2,180  706  —  (76) 2,810  2,054  707  —  2,761  6.1  1.8 
U.S. 905  681  —  —  1,586  871  684  —  1,555  3.8  2.0 
Intl 1,275  25  —  (76) 1,224  1,183  23  —  1,206  7.8  1.6 
Total Cancer Diagnostics 96  706  —  (1) 801  —  707  —  707  n/a 13.4 
U.S. 93  681  —  —  774  —  684  —  684  n/a 13.2 
Intl 3  25  —  (1) 27  —  23  —  23  n/a 19.2 
Total Medical Devices 5,539  —  (8) (249) 5,282  4,895  —  (24) 4,871  13.2  8.5 
U.S. 2,523  —  (8) —  2,515  2,339  —  (24) 2,315  7.9  8.7 
Intl 3,016  —  —  (249) 2,767  2,556  —  —  2,556  18.0  8.3 
Total Structural Heart* 578  —  (8) (29) 541  —  531  —  (24) 507  9.0  6.8 
U.S. 224  —  (8) —  216  —  248  —  (24) 224  (9.5) (3.6)
Intl 354  —  —  (29) 325  —  283  —  —  283  25.2  15.0 

*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.
(a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
(b) Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.






Page 13 of 15


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Quarter Ended March 31, 2026 and 2025
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ 2  $ 7  $ 422  $ 1  $ 432 
R&D (1) (10) —  (13) (24)
SG&A (444) (33) —  4  (473)
Other (income) expense, net (2) (2) —  (3) (7)
Earnings before taxes $ 449  $ 52  $ 422  $ 13  936 
Taxes on Earnings (d) (9)
Net Earnings $ 945 
Diluted Earnings per Share $ 0.54 
The table above provides additional details regarding the specified items described on page 11.

a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 14 of 15


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Quarter Ended March 31, 2025
(in millions, except per share data)
(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds
Gross Margin $ —  $ 26  $ 420  $ 2  $ 448 
R&D (1) (16) —  (10) (27)
SG&A (3) (7) —  —  (10)
Other (income) expense, net (24) —  —  (11) (35)
Earnings before taxes $ 28  $ 49  $ 420  $ 23  520 
Taxes on Earnings (d) (74)
Net Earnings $ 594 
Diluted Earnings per Share $ 0.33 

The table above provides additional details regarding the specified items described on page 11.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses as well as a fair value adjustment to contingent consideration related to a business acquisition.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment impairment charges.
d)Reflects the net tax benefit associated with the specified items. 2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 15 of 15